REVLIMID ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
28	全身性アミロイドーシス	5

28. 全身性アミロイドーシス

臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-001405-41-DE (EUCTR)	24/10/2008	28/08/2008	A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated p ...	A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated p ...	AL amyloidosis	Trade Name: Revlimid Other descriptive name: Lenalidomide Trade Name: Alkeran Product Code: L01AA03 Othe ...	GMIHO mbH	NULL	Not Recruiting			Female: yes Male: yes			Germany
2	EUCTR2007-006037-13-IT (EUCTR)	21/02/2008	10/12/2007	An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previous ...	An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previous ...	amyloidosis AL MedDRA version: 6.1;Level: PT;Classification code 10002022	Trade Name: Revlimid INN or Proposed INN: Cyclophosphamide INN or Proposed INN: Dexamethasone	OSPEDALE POLICLINICO S. MATTEO	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Italy
3	NCT00564889 (ClinicalTrials.gov)	December 2007	28/11/2007	Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloid ...	A Phase II Trial of Lenalidomide (Revlimid®), Cyclophosphamide and Dexamethasone in Patients With Pr ...	Multiple Myeloma and Plasma Cell Neoplasm	Drug: cyclophosphamide;Drug: dexamethasone;Drug: lenalidomide	Mayo Clinic	National Cancer Institute (NCI)	Completed	18 Years	N/A	All	35	Phase 2	United States
4	EUCTR2006-007082-36-GR (EUCTR)	16/10/2007	18/07/2007	A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethason ...	A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethason ...	Primary (AL) amyloidosis in untreated patients or patientsw who have failed prior treatments	Trade Name: REVLIMID Trade Name: Endoxan Trade Name: Dexamethasone Trade Name: REVLIMID INN or Proposed ...	Hellenic Oncology Cooperative Group	NULL	Not Recruiting			Female: yes Male: yes	55	Phase 1/2	Greece
5	NCT00166413 (ClinicalTrials.gov)	April 2005	12/9/2005	Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis	A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis	Amyloidosis	Drug: CC-5013	Mayo Clinic	NULL	Completed	18 Years	N/A	Both	38	Phase 2	United States

First Previous1Next Last